Utilization and Payment of ERCP-related Operations and Medical Supplies in China BMI Inpatients

B. Cui,L. Wang,X. Xiong,J. Li
DOI: https://doi.org/10.1016/j.jval.2015.03.1575
IF: 5.156
2015-01-01
Value in Health
Abstract:To analyze the utilization of ERCP-related operations and medical supplies as well as their expenses and payment in China BMI inpatients, and determine whether the BMI payment policies are appropriate for these inpatients. This study used the data from the National Sample Survey on Medical Service Utilization of the BMI participants in 2012. Altogether 10,597 inpatients (2.2% of total) treated by ERCP technologies were extracted from the 375 thousands total sample inpatients of all over the country. All the actual claim data of medical expenses and medical care utilization were collected. Descriptive analysis was applied to the data and related BMI payment policies were reviewed. 1) About 948 thousands inpatients were treated by ERCP technologies in China BMI participants in 2011, 83% of them suffered from the digestive system diseases. 2) The average hospitalization medical expenses of ERCP inpatients was 11293 RMB (about 1820 USD), among which 45%, 40% and 15% were for drugs, medical services and medical supplies respectively. 3) The 32 ERCP-related operations cost more than 414 million RMB (about 67 million USD), and Top 5 high-cost operations cost 80.4%. 4) The 16 ERCP-related medical supplies cost 194 million RMB (about 31 million USD) and Top 5 cost 58%. The highest price of these medical supplies was more than 7500 RMB (about 1210 USD, i.e. enteral stent). 5) The average reimbursement rate of ERCP inpatients about 68%, 5 percents lower than that of total BMI inpatients. The ERCP technologies were effective new diagnosis and treatment methods used more widely in clinical practice at present. The medical expenses of ERCP-related inpatients were higher, while their BMI reimbursement level was lower, which meant that their economic burden were higher but could get less reimbursement from BMI. The BMI reimbursement policies on the ERCP-related operations and medical supplies should be adjusted to promote these new medical technologies.
What problem does this paper attempt to address?